Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Tenofovir Alafenamide in Chronic Hepatitis B with Renal or Hepatic Impairment
NCT03180619Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Started Jun 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03180619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180619.